A method for preparing isophorone diisocyanate by (1) reacting isophorone with hydrogen cyanide in the presence of a catalyst to obtain isophorone nitrile; (2) reacting the isophorone nitrile obtained in step (1) with ammonia gas and hydrogen in the presence of a catalyst to obtain isophorone diamine; and (3) subjecting the isophorone diamine to a phosgenation reaction to obtain the isophorone diisocyanate, wherein the content of impurities containing a secondary amine group in the isophorone diamine that undergoes the phosgenation reaction in step (3) is ?0.5 wt. The method reduces the content of hydrolyzed chlorine in the isophorone diisocyanate product, improves the yellowing resistance of the product, and the harm due to presence of hydrolyzed chlorine in the product is reduced.

A method for preparing isophorone diisocyanate by (1) reacting isophorone with hydrogen cyanide in the presence of a catalyst to obtain isophorone nitrile; (2) reacting the isophorone nitrile obtained in step (1) with ammonia gas and hydrogen in the presence of a catalyst to obtain isophorone diamine; and (3) subjecting the isophorone diamine to a phosgenation reaction to obtain the isophorone diisocyanate, wherein the content of impurities containing a secondary amine group in the isophorone diamine that undergoes the phosgenation reaction in step (3) is ?0.5 wt. The method reduces the content of hydrolyzed chlorine in the isophorone diisocyanate product, improves the yellowing resistance of the product, and the harm due to presence of hydrolyzed chlorine in the product is reduced.

Phenyl cyclohexanone based active agents, pharmaceutical preparations containing such active agents, methods of modifying cellular activity by contacting cells with such active agents, and methods of treating various conditions by administering such active agents to a patient are described.

Provided herein, in part, are compounds and compositions useful for preparing pralsetinib. Also provided herein are processes for preparing pralsetinib.

This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions containing such molecules, and processes of using such pesticidal compositions against such pests. These pesticidal compositions may be used, for example, as acaricides, insecticides, miticides, molluscicides, and nematicides. This document discloses molecules having the following formula (Formula One). ##STR00001##

This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions containing such molecules, and processes of using such pesticidal compositions against such pests. These pesticidal compositions may be used, for example, as acaricides, insecticides, miticides, molluscicides, and nematicides. This document discloses molecules having the following formula (Formula One). ##STR00001##

Substituted cyclohexyl chemical entities of Formula (I): ##STR00001## wherein R.sup.a, G, and R.sup.b have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by nociceptin activity or dopamine signaling; treating neurological disorders, neurodegenerative diseases, depression, and schizophrenia; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including renal, respiratory, gastrointestinal, liver, genitourinary, metabolic, and inflammatory disorders.

Substituted cyclohexyl chemical entities of Formula (I): ##STR00001## wherein R.sup.a, G, and R.sup.b have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by nociceptin activity or dopamine signaling; treating neurological disorders, neurodegenerative diseases, depression, and schizophrenia; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including renal, respiratory, gastrointestinal, liver, genitourinary, metabolic, and inflammatory disorders.

The present disclosure relates generally to eukaryotic initiation factor 2B modulators of formula A, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof and methods of making and using thereof.

##STR00001##

The present disclosure relates generally to eukaryotic initiation factor 2B modulators of formula A, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof and methods of making and using thereof.

##STR00001##